Non Alcoholic Fatty Liver Disease Clinical Trial
Official title:
Genetics of Fatty Liver Disease in Childhood Obesity.
This is a study to investigate genetic predisposition to hepatic steatosis and the expression
of gluconeogenic and lipogenic genes in livers of obese children and adolescents.
Hypothesis 1: Common variants recently associated with variation in plasma TG levels
identified in Genome Wide Association Studies (GWAS) (such as GCKR, PNPLA3) can affect
accumulation of fat and subsequent development of Non Alcoholic Fatty Liver Disease (NAFLD).
Gene variants act in additive or synergistic manner with progressive liver fat accumulation
per additional risk allele.
Hypothesis 2: With increase in hepatic fat content NASH and fibrosis will increase.
Furthermore, expression of lipogenic markers (SREBP1c) will increase.
To establish a cohort of obese youths to prospectively analyze potential factors (genetic and nutritional factors) that might affect the expression and progression of NAFLD. This study will determine genetic markers and their ability to convey susceptibility to NAFLD in obese children and adolescents. Furthermore, potential mechanisms that might contribute to the accumulation of hepatic Triglyceride (TG) accumulation will be, for the first time, assessed by genotyping. Additionally, we will examine the presence of intestinal microbiome in the development of fatty liver through stool collection. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT02248311 -
"Preventing Cardiovascular Ischemic Events and Arresting Their Consequences in Type 2 Diabetic Population
|
N/A | |
| Completed |
NCT01277237 -
The Effect Of Omega-3 Fatty Acids on Non-alcoholic Fatty Liver Disease
|
Phase 3 | |
| Active, not recruiting |
NCT04442620 -
Prevention and Reversion of NAFLD in Obese Patients With Metabolic Syndrome by Mediterranean Diet and Physical Activity
|
N/A | |
| Completed |
NCT01999101 -
Safety Pilot Study of Farnesoid X Receptor (FXR) Agonist in Non-alcoholic Fatty Liver Disease (NAFLD) Patients
|
Phase 2 | |
| Completed |
NCT01327443 -
Exercise Versus Diet in the Treatment of Nonalcoholic Fatty Liver Disease
|
N/A | |
| Active, not recruiting |
NCT01482065 -
The Sleep, Liver Evaluation and Effective Pressure Study
|
N/A | |
| Completed |
NCT03135873 -
Mastiha Treatment for Obese With NAFLD Diagnosis
|
N/A | |
| Completed |
NCT02686476 -
Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes
|
N/A | |
| Completed |
NCT02820285 -
Characterization of Immune Semaphorin in Non Alcoholic Fatty Liver Disease and NASH
|
N/A | |
| Completed |
NCT01556113 -
Genetic Effect on Omega 3 Fatty Acids for the Treatment of Fatty Liver Disease
|
N/A | |
| Recruiting |
NCT06080386 -
UDFF Performance Evaluation ((Ultrason Derived Fat Fraction)
|
||
| Terminated |
NCT02134522 -
The Role of Obstructive Sleep Apnea in Children With Fatty Liver Disease
|
N/A | |
| Completed |
NCT01553500 -
Glucomannan Effects on Children With Non-alcoholic Fatty Liver Disease
|
Phase 2 | |
| Completed |
NCT05426382 -
A Digital Solution for Individuals With Non Alcoholic Fatty Liver Disease
|
N/A | |
| Completed |
NCT03300661 -
Non Alcoholic Fatty Liver Disease: Nutritional Epidemiology and Lifestyle Medicine
|
N/A | |
| Not yet recruiting |
NCT02178839 -
The Effect of Oral β- Glucan Supplement on Appetite and Insulin Resistance in Non Alcoholic Fatty Liver Disease
|
N/A | |
| Recruiting |
NCT02038387 -
Prospective Clinical Study of the Role of the Immune Response, in Relation to Diet, in Patients Affected by Either Chronic Hepatitis C Virus (HCV) Infection or Non Alcoholic Fatty Liver Disease (NAFLD)
|
N/A | |
| Completed |
NCT01874249 -
Non Invasive Assessment of Liver Fibrosis in Fatty Liver Disease
|
N/A | |
| Completed |
NCT01634048 -
The Effect of Protein-enriched Diet on Body Composition and Appetite
|
N/A | |
| Terminated |
NCT01842282 -
Amlexanox for Type 2 Diabetes and Obesity
|
Phase 2 |